Objective: To evaluate the effects of four weeks of ®sh oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males. Design and subjects: Very low density lipoprotein (VLDL) apolipoprotein B100 (apoB100) kinetics in ten healthy, white males, aged 22±43 y (mean 32 y) were investigated using a 13 C-leucine technique and gas chromatography-mass spectrometry before and after ®sh oil supplementation. Intervention: All subjects received 10 g (1.8 g EPA, 1.2 g DHA)ad of ®sh oil concentrate for four weeks. Results: Fish oil supplementation resulted in a decrease of total plasma VLDL (mean AE s.d. 1.11 AE 0.41 vs 0.87 AE 0.28 mmolal, P`0.05) and triacylglycerol concentrations (0.74 AE 0.27 vs 0.48 AE 0.21 mmolal, P`0.01). VLDL apoB100 pool size was decreased without alteration of the fractional synthetic rate but a signi®cant decrease of apoB100 production (2.23 AE 0.90 vs 1.54 AE 0.52 mgadlah, P`0.02). Following ®sh oil supplementation plasma concentrations of glucose and insulin as well as lipoprotein and hepatic lipase activities were unchanged. Fasting plasma concentrations of non-esteri®ed fatty acid (NEFA) were decreased (0.45 AE 0.12 vs 0.33 AE 0.10 mmolal, P`0.05). Conclusions: Dietary supplementation with ®sh oil in healthy males results in decreased VLDL-triacylglycerol concentrations through a decrease in VLDL particle synthesis. The decrease in NEFA substrate supply also contributes. Sponsorship: Fish oil (Maxepa 1 ) was supplied by Seven Seas Ltd, Hull, England, free of charge. Dr OAF Bodamer was funded by the`Deutsche Forschungsgemeinschaft' (Bo 1193a1-2).